# Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

> **NCT04575194** · PHASE4 · UNKNOWN · sponsor: **National and Kapodistrian University of Athens** · enrollment: 40 (estimated)

## Conditions studied

- Obesity
- Blood Pressure

## Interventions

- **DRUG:** Liraglutide 6 MG/ML [Saxenda]
- **DRUG:** Naltrexone-Bupropion Combination

## Key facts

- **NCT ID:** NCT04575194
- **Lead sponsor:** National and Kapodistrian University of Athens
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-08
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04575194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04575194, "Study of the Cardiometabolic Effects of Obesity Pharmacotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04575194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*